R. Bugat

9.9k total citations
181 papers, 6.5k citations indexed

About

R. Bugat is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, R. Bugat has authored 181 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 111 papers in Oncology, 42 papers in Molecular Biology and 35 papers in Pulmonary and Respiratory Medicine. Recurrent topics in R. Bugat's work include Colorectal Cancer Treatments and Studies (34 papers), Cancer Treatment and Pharmacology (34 papers) and Cancer therapeutics and mechanisms (29 papers). R. Bugat is often cited by papers focused on Colorectal Cancer Treatments and Studies (34 papers), Cancer Treatment and Pharmacology (34 papers) and Cancer therapeutics and mechanisms (29 papers). R. Bugat collaborates with scholars based in France, United States and Switzerland. R. Bugat's co-authors include Pierre Canal, Sylvie M. Guichard, Isabelle Hennebelle, Étienne Chatelut, J. L. Valatx, Philippe Rougier, Olivier Bouché, Patrice Herait, Stéphane Culine and Rosine Guimbaud and has published in prestigious journals such as Nature, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

R. Bugat

179 papers receiving 6.3k citations

Peers

Countries citing papers authored by R. Bugat

Since Specialization

Citations

This map shows the geographic impact of R. Bugat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Bugat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Bugat more than expected).

Fields of papers citing papers by R. Bugat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Bugat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Bugat. The network helps show where R. Bugat may publish in the future.

Co-authorship network of co-authors of R. Bugat

This figure shows the co-authorship network connecting the top 25 collaborators of R. Bugat. A scholar is included among the top collaborators of R. Bugat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Bugat. R. Bugat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	PCN28 COST SAVINGS WITH FERRIC CARBOXYMALTOSE THROUGH ITS IMPACT ON ERYTHROPOÏESIS-STIMULATING AGENTS AND BLOOD TRANSFUSION IN CHEMOTHERAPY-INDUCED ANEMIA OF BREAST AND GASTROINTESTINAL CANCER: FRENCH HEALTH CARE PAYER PERSPECTIVE 2011 ·Value in Health ·É. Luporsi, L. Mahi, Charles E. Moore, (unknown), R. Bugat	1
2	A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802) 2009 ·Annals of Oncology ·Marc Ychou, Jean‐Luc Raoul, Jean‐Yves Douillard, S. Gourgou-Bourgade, R. Bugat, Laurent Mineur, F. Viret, Y. Bécouarn, Olivier Bouché, E. Gamelin, Michel Ducreux, Thierry Conroy, Julia Seitz, Laurent Bedenne, A. Kramar	127
3	Patient-Reported Outcomes as a Component of the Primary Endpoint in a Double-Blind, Placebo-Controlled Trial in Advanced Pancreatic Cancer 2008 ·Journal of Pain and Symptom Management ·(unknown), (unknown), (unknown), Joan Maurel, (unknown), (unknown), (unknown), (unknown), R. Bugat	21
4	Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma 2006 ·Gastroentérologie Clinique et Biologique ·Emmanuel Mitry, Michel Ducreux, Mahmoud Ould-Kaci, Valérie Boige, Jean‐François Seitz, R. Bugat, (unknown), Olivier Bouché, Pierre-Luc Etienne, Jean‐Marie Tigaud, F. Morvan, Esteban Cvitkovic, Philippe Rougier	33
5	A phase I clinical and pharmacokinetic study of capecitabine (Xeloda®) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours 2005 ·British Journal of Cancer ·Jean‐Pierre Delord, Jean‐Yves Pierga, Véronique Dièras, F. Bertheault-Cvitkovic, F Turpin, François Lokiec, Isabelle Lochon, Étienne Chatelut, Pierre Canal, Rosine Guimbaud, D. Méry-Mignard, (unknown), (unknown), R. Bugat	21
6	[Demography of oncologic practitioners working in France. Projection elements for the next 30 years]. 2004 ·PubMed ·(unknown), Jean‐Pierre Delord, Pascale Grosclaude, (unknown), R. Bugat	6
7	Démographie des oncologues praticiens en exercice en France 2004 ·Bulletin du Cancer ·(unknown), Jean‐Pierre Delord, Pascale Grosclaude, (unknown), Alain Grand, R. Bugat	7
8	Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients 2004 ·Cancer Chemotherapy and Pharmacology ·Saı̈k Urien, Étienne Brain, R. Bugat, Xavier Pivot, Isabelle Lochon, (unknown), (unknown), (unknown)	51
9	Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients 2004 ·Annals of Oncology ·Michel Ducreux, Emmanuel Mitry, Mahmoud Ould-Kaci, Valérie Boige, J. F. Seitz, R. Bugat, J.L. Breau, Olivier Bouché, Pierre-Luc Etienne, Jean‐Marie Tigaud, F. Morvan, Esteban Cvitkovic, P. Rougier	73
10	[Standards, Options and Recommendations for the management of patient with carcinoma of unknown primary site]. 2002 ·PubMed ·R. Bugat, A Bataillard, Thierry Lesimple, Jean‐Jacques Voigt, Stéphane Culine, Alain Lortholary, Yacine Merrouche, G. Ganem, Marie‐Christine Kaminsky, Sylvie Négrier, M. Pérol, (unknown), Pierre Bédossa, G. Bertrand, Jean‐Michel Coindre, Karim Fizazi, (unknown)	17
11	[Adverse effects of anticancer drugs: apropos of a pharmacovigilance study at a specialized oncology institution]. 2001 ·PubMed ·(unknown), Maryse Lapeyre‐Mestre, C Bonhomme, R. Bugat, Jean‐Louis Montastruc	22
12	Tolérance de l'oxaliplatine dans le traitement des cancers colorectaux métastasés 2001 ·Bulletin du Cancer ·R. Bugat	1
13	Population pharmacokinetics of topotecan: intraindividual variability in total drug 2000 ·Cancer Chemotherapy and Pharmacology ·(unknown), (unknown), François Lokiec, Frédéric Pinguet, Stéphane Culine, R. Déporte-Féty, Nicolas Albin, Brigitte Laguerre, A Goupil, R. Bugat, Pierre Canal, Étienne Chatelut	30
14	PP14. Cost of serious adverse drug reactions related to anti-cancer chemotherapy 1997 ·European Journal of Cancer ·(unknown), Maryse Lapeyre‐Mestre, C Bonhomme, R. Bugat, (unknown)	1
15	Multifactorial mechanism for the potentiation of cisplatin (CDDP) cytotoxicity by all-trans retinoic acid (ATRA) in human ovarian carcinoma cell lines 1997 ·British Journal of Cancer ·(unknown), (unknown), Corinne Lafon, Isabelle Lochon, A Nehmé, Annie Valette, Pierre Canal, R. Bugat, S. Jozan	29
16	How to predict carboplatin clearance from standard morphological and biological characteristics in obese patients 1997 ·Annals of Oncology ·(unknown), Rosine Guimbaud, Étienne Chatelut, Christine Chevreau, R. Bugat, Pierre Canal	31
17	Association of the Philadelphia chromosome and 5q− in secondary blood disorder 1988 ·Cancer Genetics and Cytogenetics ·Nicole Dastugue, Cécile Demur, (unknown), R. Bugat, Michel Attal, G. Bourrouillou, P Colombiès	13
18	Cancers du rectum: radiothérapie pré-opératoire (344 cas). 1983 ·Bulletin du Cancer ·(unknown), (unknown), A Naja, (unknown), R. Bugat, (unknown), (unknown)	3
19	Gastric mucosal lesions produced by intravenous infusion of aspirin in cats. 1976 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·R. Bugat, Michael R. Thompson, D. Aures, Morton I. Grossman	79
20	[Localization of HBsAg, immunoglobulins, fibrin and C3 in the liver by direct immunoflourescence]. 1976 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·Claudine Orfila, M Duffaut, (unknown), (unknown), R. Bugat, (unknown)	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact